Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos-Reference-Cited by-同舟云学术

Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos

Published:2024-01-17 Issue:3 Volume:20 Page:
ISSN:2049-9434
Container-title:Biomedical Reports
language:
Short-container-title:Biomed Rep

Author:

Yagolovich Anne¹,Kuskov Andrey²,Kulikov Pavel²,Bagrov Dmitry¹,Petrova Polina¹,Kukovyakina Ekaterina²,Isakova Alina²,Khan Irina³,Pokrovsky Vadim³,Nosyrev Alexander⁴,Stamati Polyxeni⁵,Markvicheva Elena⁶,Gasparian Marine²,Spandidos Demetrios⁷,Tsatsakis Aristidis⁴

Affiliation:

1. Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russian Federation

2. D. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russian Federation

3. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, Russian Federation

4. Center of Bioanalytical Research and Molecular Design, Sechenov First Moscow State Medical University, 119991 Moscow, Russian Federation

5. Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece

6. Shemyakin‑Ovchinnikov Institute of Bioorganic Chemistry of The Russian Academy of Sciences, 117997 Moscow, Russian Federation

7. Laboratory of Clinical Virology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece

Publisher

Spandidos Publications

Reference39 articles.

1. Proteasome: An emerging target for cancer therapy;Zavrski;Anticancer Drugs,2005

2. Development of the proteasome inhibitor Velcade (Bortezomib);Adams;Cancer Invest,2004

3. Velcade (Bortezomib) receives 2 new FDA indications: For retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma;Raedler;Am Health Drug Benefits,2015

4. The safety of bortezomib for the treatment of multiple myeloma;Cengiz Seval;Expert Opin Drug Saf,2018

5. Pathological mechanisms of bortezomib-induced peripheral neuropathy;Yamamoto;Int J Mol Sci,2021